These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7726306)

  • 1. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
    Mavissakalian MR; Perel JM
    Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1989 Feb; 46(2):127-31. PubMed ID: 2643933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipramine in the treatment of agoraphobia: dose-response relationships.
    Mavissakalian M; Perel J
    Am J Psychiatry; 1985 Sep; 142(9):1032-6. PubMed ID: 3895987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Am J Psychiatry; 1992 Aug; 149(8):1053-7. PubMed ID: 1636805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian M; Perel JM
    Arch Gen Psychiatry; 1992 Apr; 49(4):318-23. PubMed ID: 1558466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipramine treatment of panic disorder with agoraphobia: the second time around.
    Mavissakalian MR; Perel JM; de Groot C
    J Psychiatr Res; 1993; 27(1):61-8. PubMed ID: 8515390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
    Modigh K; Westberg P; Eriksson E
    J Clin Psychopharmacol; 1992 Aug; 12(4):251-61. PubMed ID: 1527228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
    Schweizer E; Patterson W; Rickels K; Rosenthal M
    Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response characterization of the antipanic effects of imipramine.
    Mavissakalian MR; Perel JM
    Psychopharmacol Bull; 1994; 30(2):171-4. PubMed ID: 7831451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
    Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
    J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A naturalistic study of imipramine in panic disorder and agoraphobia.
    Aronson TA
    Am J Psychiatry; 1987 Aug; 144(8):1014-9. PubMed ID: 3300374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia.
    Mavissakalian M
    J Clin Psychiatry; 1990 May; 51(5):184-8. PubMed ID: 2335493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
    de Groot CM; Mavissakalian MR
    J Clin Psychopharmacol; 1994 Apr; 14(2):107-10. PubMed ID: 8195450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks.
    Mavissakalian M; Perel J; Bowler K; Dealy R
    Am J Psychiatry; 1987 Jun; 144(6):785-7. PubMed ID: 3296792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.